Nasdaq Stockholm AB: Clinical Laserthermia Systems receives observation status (140/19)

Yesterday, on April 15, 2019, Clinical Laserthermia Systems (the "Company")
published a press release with information that Nasdaq Stockholm has referred a
disciplinary matter concerning the Company to its Disciplinary Committee, and
that the background to the matter is incorrect information by the Company on
its agreement with its CEO. 

The current rules of Nasdaq First North state that a listed company can be
given observation status if any circumstance exists that result in substantial
uncertainty regarding the company or the pricing of its listed financial
instruments. 

Given that the Exchange has found that the Company has committed a serious
breach of the Nasdaq First North Nordic Rulebook and has referred the matter to
its Disciplinary Committee, questioning whether the Company is suitable to be
listed on Nasdaq First North, the Exchange has decided that the shares in
Clinical Laserthermia Systems AB (CLS B, ISIN code SE0002756130, order book ID
65182) shall be given observation status. 

For further information concerning this exchange notice please contact Elias
Skog or Karin Ydén, telephone + 46 8 405 60 00.